Loading
Life sciences · Journal article
International Surgery Journal · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become a cornerstone in the management of type 2 diabetes mellitus and obesity because of their proven metabolic and cardiovascular benefits. As their clinical use continues to expand, increasing attention has been directed toward their potential ophthalmic effects. This narrative review summarizes the current evidence regarding the biological mechanisms, therapeutic potential, and ocular safety profile of GLP-1RAs across medical and surgical ophthalmology. Experimental studies demonstrate that GLP-1 receptors are expressed in multiple ocular tissues and that receptor activation exerts anti-inflammatory, antioxidant, vasculoprotective, and neuroprotective effects through modulation of oxidative stress, mitochondrial homeostasis, and retinal cell survival. Clinically, evidence from cardiovascular outcome trials initially raised concern regarding diabetic retinopathy progression, particularly following the SUSTAIN-6 trial. However, subsequent randomized trials, observational studies, and recent systematic reviews have not demonstrated a consistent class-wide increase in diabetic retinopathy risk. Current evidence suggests that the reported retinal complications are more likely associated with advanced baseline retinal disease and rapid glycemic improvement than with direct retinal toxicity. Emerging data also indicate potential applications in glaucoma, retinal neuroprotection, age-related macular degeneration, and ocular surface disease, although these findings remain largely supported by preclinical or observational evidence. A possible association between semaglutide and nonarteritic anterior ischemic optic neuropathy has recently been reported, but available evidence is insufficient to establish causality. Overall, GLP-1RAs appear to maintain a favorable ocular safety profile while offering promising therapeutic opportunities beyond metabolic disease. Future prospective ophthalmology-specific studies are needed to clarify their long-term ocular effects, identify patients at increased risk of retinal complications, and determine whether their experimental neuroprotective properties translate into clinically meaningful benefits.